Table 1.

Clinical features of study patients

CharacteristicAntithrombotic therapy failure, n = 29, Group A1 and A2No failure, n = 23, Group Bp Value
χ2-test with continuity correction was used for categorical variables. Fisher’s exact test was used for carotid endarterectomy. Student’s t-test was used for age.
* Comparison of antithrombotic therapy received in Group B with the therapy after the initial event in Group A2 and therapy at the time of the initial stroke/TIA attributed to intracranial stenosis in Group A1 (see figure).
WASID = Warfarin Versus Aspirin for Symptomatic Intracranial Disease.
Age, y (SD, range)67.9 (12.6, 31.4–89.4)65.1 (12.6, 31–77.4)0.419
Men/women19/1012/110.491
Race, n (%)
Caucasian23 (79.3)11 (47.8)0.038
Non-Caucasian6 (20.7)12 (52.2)
Hypertension, n (%)21 (72.4)17 (73.9)1.000
Diabetes, n (%)6 (20.7)8 (34.8)0.410
Hyperlipidemia, n (%)15 (51.7)5 (21.7)0.055
Ever smoked, n (%)13 (44.8)9 (39.1)0.896
Coronary artery disease, n (%)7 (24.1)5 (21.7)1.000
Previous TIA or stroke, n (%)7 (24.1)4 (17.4)0.803
Previous carotid endarterectomy, n (%)3 (10.3)1 (4.3)0.621
Anterior circulation stenosis, n (%)9 (31.0)12 (52.2)0.208
Posterior circulation stenosis, n (%)20 (69.0)11 (47.8)
Presentation with stroke, n (%)10 (34.5)13 (56.5)0.191
Treatment, n (%)
Warfarin9 (31.0)19 (82.6)0.001*
Antiplatelet agents16 (55.2)3 (13.0)
Heparin4 (13.8)0
WASID trial01 (4.4)
Presence of additional intracranial or extracranial stenosis or occlusion, n (%)9 (31.0)5 (21.7)0.663